Untreated hearing loss ranks as the single largest modifiable risk factor for dementia, outweighing smoking, high blood pressure, and obesity, according to the 2024 report of the Lancet standing Commission on dementia prevention, intervention, and care. The Commission’s updated life-course model calculates population-attributable fractions for 14 risk factors and finds that hearing impairment accounts for a greater share of preventable dementia cases than any other individual factor. With dementia numbers projected to climb sharply in the decades ahead, the finding puts a sharp spotlight on a condition that can often be treated with widely available hearing aids.
Why the hearing–dementia link demands attention right now
The Lancet Commission’s conclusion did not appear overnight. A foundational 2011 prospective cohort study led by Frank Lin at Johns Hopkins established a dose–response association between baseline hearing loss and later diagnoses of all-cause dementia and Alzheimer’s disease. Participants with greater hearing deficits faced proportionally higher risk. That early evidence set the stage for the Commission’s own work, which first identified hearing loss from midlife onward as the largest potentially modifiable factor for dementia risk in its 2017 analysis.
The 2024 update sharpens that ranking. By recalculating attributable fractions across an expanded set of 14 modifiable risk factors, the Commission reports that nearly half of all dementia cases worldwide could theoretically be prevented or delayed if every known risk were eliminated. Hearing loss sits at the top of that list, giving it outsized policy and clinical relevance at a time when aging populations in the United States and globally are driving dementia prevalence higher. The message is not that hearing aids eliminate dementia, but that managing hearing throughout adulthood could meaningfully shift the odds at a population level.
One hypothesis that researchers have begun to explore is whether early intervention with professionally fitted hearing aids can slow structural brain changes, specifically the accumulation of white-matter hyperintensities visible on MRI, over a decade compared with matched peers who delay treatment. No long-term imaging trial has yet confirmed that specific outcome. But the logic tracks with the Commission’s framework: if sensory deprivation accelerates neurodegeneration, restoring auditory input early should preserve brain tissue. Testing that idea will require large-scale, decade-long randomized imaging studies that do not yet exist.
Three waves of evidence behind the Commission’s claim
The case rests on three distinct layers of research, each stronger than the last. First came observational data. Lin and colleagues showed in their Archives of Neurology study that hearing loss predicted incident dementia even after adjusting for age, sex, and other confounders. That finding was replicated in multiple cohorts worldwide, giving the Lancet Commission enough confidence to feature hearing loss prominently in its initial report on dementia risk.
Second, the Commission refined its statistical model. The 2020 update from the Lancet group on dementia prevention and care, available as an open-access Commission report, formally positioned hearing impairment as a leading midlife modifiable risk factor and published population-attributable fraction estimates that public-health agencies adopted widely. Those estimates quantify how many dementia cases in a population can be attributed to a single risk factor, assuming a causal relationship. Hearing loss consistently produced the highest individual fraction among all factors examined, outstripping better-known contributors such as hypertension, diabetes, and late-life depression.
Third, intervention evidence arrived. The ACHIEVE trial, a multicentre randomized controlled trial conducted across sites in the United States, tested whether a hearing-aid-based intervention could slow cognitive decline over roughly three years compared with a health-education control group. Participants assigned to the hearing intervention received comprehensive audiologic care, including hearing aids, counseling, and follow-up adjustments, while the control group received structured education on general health topics unrelated to hearing.
Early results pointed to cognitive benefits in a prespecified higher-risk subgroup, providing the first experimental support for the idea that treating hearing loss can protect thinking skills. In that subgroup-older adults with greater baseline risk for cognitive decline-the hearing intervention slowed deterioration on a global cognitive composite compared with the control condition. The effect was modest but clinically meaningful, especially given the relatively short follow-up window for a neurodegenerative outcome.
That trial moved the conversation from correlation to the beginnings of causal proof, which is why the 2024 Commission felt confident labeling hearing loss not just a risk factor but a reversible one. While no single study can settle causality, ACHIEVE demonstrates that a real-world hearing intervention can alter cognitive trajectories, at least for some older adults. Combined with decades of observational data, this gives policymakers and clinicians a more solid footing for recommending routine hearing assessment and timely treatment.
The 2024 Commission analysis synthesizes all three evidence streams into a single recommendation: address hearing loss as a public-health priority for dementia prevention. In practical terms, that means integrating hearing screening into midlife health checks, reducing financial and logistical barriers to hearing-aid access, and ensuring that primary-care clinicians treat hearing complaints as more than a quality-of-life issue.
Gaps in the data and what to watch next
Despite the strength of the Commission’s conclusion, several questions remain open. The ACHIEVE trial ran for approximately three years, a relatively short window for measuring cognitive decline, which typically unfolds over a decade or more. Whether hearing-aid use sustains its protective effect over longer periods is unknown. The trial’s primary outcome showed a benefit concentrated in a higher-risk subgroup rather than across the full study population, raising questions about who gains the most from early intervention and how best to target limited resources.
The population-attributable fraction estimates themselves carry uncertainty. They assume a causal relationship between hearing loss and dementia, but observational data alone cannot rule out shared underlying causes, such as vascular disease or genetic predisposition, that might drive both conditions independently. The Commission acknowledges this limitation while arguing that the weight of converging evidence justifies action even before every mechanistic question is settled. In public health, waiting for perfect proof can mean missing a window where relatively simple interventions might avert substantial harm.
Imaging-based endpoints, like white-matter hyperintensity progression, have not been tested in a hearing-intervention trial of sufficient size and duration. Such a study would require thousands of participants, standardized MRI protocols, and long-term follow-up-an expensive undertaking that has yet to be funded at scale. Without those data, researchers must infer mechanisms indirectly from cognitive outcomes, structural brain differences observed in cross-sectional imaging, and animal models of sensory deprivation.
Another unresolved issue is timing. The Commission emphasizes midlife hearing loss, typically defined as occurring between ages 45 and 65, as especially important. Yet most people who eventually receive hearing aids do so years later, often after substantial auditory deprivation has already occurred. It remains unclear whether very early intervention, perhaps at the first signs of measurable threshold shifts, would yield larger cognitive benefits than treatment initiated in later life. Answering that question will require trials that enroll participants earlier in the hearing-loss trajectory and follow them for longer than ACHIEVE did.
Equity also looms large. Access to hearing care varies widely by income, geography, and health-insurance coverage. If hearing loss is indeed the top modifiable dementia risk factor, then unequal access to hearing aids risks widening existing disparities in cognitive health. Policy responses could include subsidized devices for low-income adults, expanded coverage for audiologic services, and investment in community-based screening programs that reach people who rarely see specialists.
For now, the Commission’s message is straightforward: hearing loss is not an inevitable, benign companion of aging but a modifiable condition with implications for brain health. While scientists continue to refine the numbers and probe the biology, the practical steps are clear enough-identify hearing problems early, make treatment affordable and acceptable, and integrate hearing care into broader dementia-prevention strategies. In the context of a global dementia burden that is projected to rise for decades, ignoring such a tractable risk factor would be a missed opportunity.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
